Biodesix, Inc., a Boulder, CO-basedĀ molecular diagnostics company advancing the development of innovative products for personalizing medicine, closed on $8.8m in Series D financing.
Backers included unnamed existing shareholders.
Led by CEO David Brunel, Biodesix has developed VeriStrat, a serum protein test that helps physicians guide therapy for patients with advanced non-small cell lung cancer (NSCLC).
The company intends to use the funds for ongoing development of its technology platform and expansion of sales and marketing efforts to support VeriStrat.
FinSMEs
12/04/2013